This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo

Biocon Ltd has announced receiving US FDA approval for their biosimilar Pebrilzo, which treats HER2-positive breast cancer. This milestone adds to Biocon's portfolio, increasing their number of oncology biosimilars approved in the United States to five. The company has also secured a global settlement with Genentech for Pebrilzo's earliest licensed launch date in 2028.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5fuliF
via IFTTT

Glenmark launches generic of Inlyta tablets for kidney cancer treatment in US

Glenmark Pharmaceuticals Inc has announced the launch of Axitinib Tablets in the United States in two strengths. These tablets are a generic version of Pfizer's Inlyta, used for advanced renal cell carcinoma treatment. The introduction of this product reflects Glenmark's ongoing commitment to providing affordable medicines to patients. Annual sales of Inlyta tablets reached approximately USD 538.4 million in the US during the last year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kl7eciL
via IFTTT

Dinaz Vervatwala x The Economic Times

Dinaz Vervatwala established Dinaz's Fitness, a unique women's fitness studio in Hyderabad, back in 1993. Transitioning from a career as a chartered accountant, she emerged as a prominent fitness trainer and wellness coach. Dinaz advocates for a holistic view of wellness, blending mental health and sustainable practices, drawing on her personal journey after overcoming a traumatic accident that instilled in her the values of resilience and consistency.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l4CVDmo
via IFTTT

Zydus Lifesciences completes 50:50 JV transaction with Sunshine Healthcare Lanka

In a significant strategic move, Zydus Lifesciences Ltd has secured a 50 percent interest in Zydus Sunshine Lifesciences Pvt Ltd, forging a joint venture with Sunshine Healthcare Lanka Limited. This partnership was concluded on November 11, 2026, following a timeline extension that pushed the original closing date from June 26, 2026, to December 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T4xhX38
via IFTTT

Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment

Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpjaMgs
via IFTTT

Beyond Business: The Leadership Philosophy of T. Kishan Singh

T. Kishan Singh highlights the influence of his father's dedication on his professional journey in the paper industry. He stresses the role of sustainable practices and customer relationships for long-term business success. Health and fitness are prioritized as essential elements for effective leadership and overall well-being. Singh shares that consistency and resilience are vital in navigating challenges, both personally and professionally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kLsVhBG
via IFTTT

Deepinder Goyal's $900 Temple wearable faces scrutiny over brain blood-flow claims

Temple, a new wearable device, claims to track blood flow to the brain and other health metrics. Indian doctors express concerns over the validity of these claims, asking for regulatory scrutiny. Some sportspersons promote the device, while critics label it a gimmick without formal medical approvals. Developer Deepinder Goyal states the device is a wellness tracker, not a medical one.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DI9zTA2
via IFTTT